Simplex Trading’s Mineralys Therapeutics MLYS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$480K Sell
19,100
-19,800
-51% -$539K ﹤0.01% 3613
2026
Q2
$1.05M Buy
38,900
+33,000
+559% +$905K ﹤0.01% 2723
2026
Q1
$160K Buy
5,900
+1,800
+44% +$52.8K ﹤0.01% 4570
2025
Q4
$149K Sell
4,100
-14,100
-77% -$565K ﹤0.01% 4541
2025
Q3
$690K Buy
+18,200
New +$394K ﹤0.01% 3444
2025
Q2
– Sell
-94,100
Closed -$1.49M – 9328
2025
Q1
$1.49M Buy
94,100
+93,400
+13,343% +$1.07M ﹤0.01% 2320
2024
Q4
$8K Hold
700
– – ﹤0.01% 7345
2024
Q3
$8K Buy
+700
New +$8.47K ﹤0.01% 7344

Other funds holding MLYS

Simplex Trading's MLYS Position: Q3 2026 in Review

Simplex Trading reduced its Mineralys Therapeutics (MLYS) stake by 9.7% in Q3 2026, selling an estimated $94.5K and leaving 32,507 shares worth $817K. The position accounts for ﹤0.01% of the portfolio, ranked #2976.

Simplex Trading first reported a position in MLYS in Q3 2024 and has held it in 8 quarters since. The position peaked at $971K in Q2 2026. 88 funds tracked by Wall St. Rank hold MLYS as of Q3 2026.

  • Simplex Trading held 32,507 shares of Mineralys Therapeutics worth $817K as of Q3 2026.
  • Simplex Trading sold 3,472 Mineralys Therapeutics shares in Q3 2026, an estimated $94.5K.
  • Mineralys Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q3 2026, its #2976 holding.
  • Simplex Trading first reported a position in Mineralys Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Simplex Trading's Mineralys Therapeutics position peaked at $971K in Q2 2026.
  • 88 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q3 2026.

Based on Simplex Trading's 13F filing for Q3 2026, filed 4 Nov 2026.